Tagamet HB® 200 relieves and prevents heartburn, acid indigestion and sour stomach. When used as directed. It contains the same ingredient found in prescription strength Tagamet. Tagamet HB® 200 reduces the production of stomach acid.

Active Ingredient   Cimetidine, 200 mg.


Allergy alert: Do not use if you are allergic to cimetidine or other acid reducers.

Do not use

Ask a doctor or pharmacist before use if you are taking

If you are not sure you are taking one of these medicines, talk to your doctor or pharmacist.

Stop use and ask a doctor if

If pregnant or breast-feeding, ask a health professional before use.

Keep out of reach of children.

In case of overdose, get medical help or contact a Poison Control Center right away.


Other Information

Inactive Ingredients   butylparaben, FD&C blue #1, flavors, microcrystalline cellulose and carboxymethylcellulose sodium, propylene glycol, propylparaben, purified water, saccharin sodium, sucrose, xanthan gum

Pharmacokinetic Interactions Cimetidine at prescription doses is known to inhibit various P450 metabolizing isoenzymes, which could affect metabolism of other drugs and increase their blood concentration. Investigation of pharmacokinetic interactions at the recommended OTC dose of cimetidine have thus far shown only small effects. A pharmacokinetic study conducted in 26 normal male subjects (mean age, 38 years) at steady state using the maximum recommended OTC dose level (200 mg twice a day), on average, increased the 24 hour AUC of theophylline by 14% and increased peak theophylline levels by 15%. This interaction should be borne in mind in advising patients on the use of Tagamet HB 200. At the prescription doses of cimetidine, clinically significant pharmacokinetic interactions between cimetidine and warfarin, phenytoin, and theophylline have been reported. At prescription doses, pharmacokinetic interactions have been reported for a number of other drugs as well, such as with dihydropyridine calcium channel blockers or some short acting benzodiazepines. At the maximum recommended OTC dose level (200 mg twice a day), a pharmacokinetic study conducted in 21 normal male subjects (mean age, 38 years) showed that Tagament HB 200, on average, increased the total AUC of triazolam by 26-28% and increased peak triazolam levels by 11-23%. The apparent terminal elimination half life of triazolam was not altered at this dosage.


NOTE: These photos can be used only for identification by shape, color, and imprint. They do not depict actual or relative size.

The product samples shown here have been supplied by the manufacturer and reproduced in full color by PDR as a quick-reference identification aid. While every effort has been made to assure accurate reproduction, please remember that any visual identification should be considered preliminary. In cases of poisoning or suspected overdosage, the drug' identity should be verified by chemical analysis.